

## **WHO WE ARE:**

Boston Pharmaceuticals was launched in late 2015 as a new pharmaceutical company model, providing a bridge to value realization for early stage clinical development programs. By offering strategic partnership options to biotech and pharmaceutical companies, our goal is to enable differentiated, under-resourced therapeutics to be developed and made available to patients with unmet medical needs. We focus primarily on clinical development from IND through Phase 2 clinical proof-of-concept (PoC). Our team leverages an average of over 20 years of drug development experience and a broad network of external resources to design and execute highly efficient, definitive clinical PoC programs, enabling our partners to advance into pivotal trials with a high probability of success. We are actively investing \$600 million of committed capital to build a diversified portfolio. We are funded by Gurnet Point Capital, a \$2 billion healthcare private equity fund.

## **WE BELIEVE IN TWO FUNDAMENTAL CONCEPTS:**

1. Many high quality drug development programs are underfunded or deprioritized, but with the appropriate development plan and investment, these candidates could bring significant value to their originators and ultimately to patients.
2. The demonstration of true clinical proof-of-concept is the key value-creation step in the clinical development of a medicine.

## **WHAT WE DO:**

We seek to acquire drug development programs from IND enabling through early Phase 2, and ultimately license or sell those that reach clinical PoC in order to create value for our organization and our partners. We are agnostic to therapeutic area, modality, and technology. Our team of scientists and clinicians have expertise across multiple disease areas, mechanisms, and molecule types. We are data driven, and demand a thorough understanding of the biology, mechanism and potential therapeutic differentiation before committing to a program. We apply a rigorous, objective approach to drug development, incorporating interim analyses and milestones in order to de-risk our investments before major capital commitments are made. Our plan is to assemble a carefully constructed portfolio of clinical candidates across a broad array of mechanisms and therapeutic targets.



## OUR DEAL MODEL:

Boston Pharmaceuticals is an operating pharmaceutical company, not an investment fund. We do not make equity investments into companies, nor do we have a fixed time horizon for capital deployment and return. Our strong capital base and unique long-term investment cycle allow us to be flexible and creative in our deal structure and financing. We work with pharmaceutical and biotech companies to partner and develop the right molecules into the best medicines.

## LEADERSHIP TEAM:

Our company is comprised of highly experienced pharmaceutical and biotechnology experts who have successfully developed and evaluated hundreds of drug candidates across all development stages during their careers.

### CHRIS VIEHBACHER, CHAIRMAN OF THE BOARD AND CO-FOUNDER

*Previous: Sanofi, CEO*

### ROB ARMSTRONG, CEO AND CO-FOUNDER

*Previous: Lilly, Head of External Research and Development*

### CONSTANTINE CHINOPOROS, CHIEF BUSINESS OFFICER

*Previous: Sanofi, VP and Chief Licensing Officer*

### IAN SANDERSON, CHIEF FINANCIAL OFFICER

*Previous: Catabasis Pharmaceuticals, Chief Financial Officer Cowen & Co, Senior Pharmaceuticals Analyst*

Our internal team now stands at 17 employees, with a combined 300+ years of pharmaceutical industry experience. We have direct clinical development experience in immunology, oncology, neurology, rare disease and infectious disease programs. Our commercialization experience spans these areas and more. We supplement our internal capabilities with a network of over 90 established consulting partners. Our expertise and operating flexibility means that we can thoroughly assess any development opportunity efficiently and be very responsive to potential partners.

*We look forward to exploring YOUR opportunities.*